Business
Inspira™ Introduces Advanced Life Support Solutions to Key International Leaders at the Annual iECOs Conference in Israel
RA'ANANA, Israel, June 17, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira
About this update from Qtrex Quantum Ltd.
[{"type":"text","content":"RA'ANANA, Israel, June 17, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the \"Company\" or \"Inspira Technologies\"), a breakthrough medical technology company, is proud to announce today that the Company will present at the annual iECOs Conference in Herzliya, Israel on June 18th, 2024.\n\nThe Company will present the INSPIRA™ ART100 System, recently 510(k) U.S. Food and Drug Administration-cleared, and which is pending approval from AMAR, the medical device division of the Israeli Ministry of Health. In addition, the Inspira Technologies research and development team will be available at its booth at the conference to answer questions about its technologies and products currently in development. To schedule a meeting with the Company, please contact: [email protected]\nAbout iECOs\niECOs, known as the Israeli ECMO Society, is a medical organization for medical professionals in the fields of ICU medicine including pediatrics, cardiac medicine and surgery, heart-lung specialists, emergency medicine and heart failure to share knowledge and professional experiences, to improve and promote extracorporeal oxygenation education and medical practice. \nAbout Inspira Technologies OXY B.H.N. Ltd.\nInspira™ Technologies is an innovative medical technology company in the life support arena. The INSPIRA™ ART (Gen 2), also known as the INSPIRA™ ART500, shall include the Company's Adaptive Blood Oxygenation technology and is being designed to continuously measure the patient's blood parameters in real-time, delivering needed oxygen volume straight into the blood. By elevating patient oxygen saturation levels in minutes, this technology potentially allows patients to remain awake during treatment and therefore may enable patients to be treated in and beyond intensive care units, reducing the need for mechanical ventilation systems that requires intubation and medically induced coma.\nThe Company received FDA 510(k) clearance for its INSPIRA ART100, a Cardiopulmonary Bypass System.\nThe Company's other products, including the INSPIRA ART (Gen 2) and HYLA™ blood sensor, have not yet been tested or used in humans and have not been approved by any regulatory entity.\nFor more information, please visit our corporate website: https://inspira-technologies.com \nForward-Looking Statement Disclaimer \nThi...